FHTX Q4 2023 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+37.9% YoY

Gross Profit

$5M85.2% margin

Operating Income

-$25M-441.3% margin

Net Income

-$24M-417.9% margin

EPS (Diluted)

$-0.57

QoQ Revenue Growth

-67.0%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$286M

Total Liabilities

$363M

Stockholders' Equity

-$77M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+37.9%
Gross Profit	$5M	-$24M	+120.5%
Operating Income	-$25M	-$32M	+20.2%
Net Income	-$24M	-$29M	+16.5%